The first and simplest MFC panel for MRD evaluation in CLL, virtually applicable to all cases, albeit with a low sensitivity, was based on CD19/CD5 co-expression with demonstration of surface Ig light chain (κ or λ) restriction (as a surrogate marker of clonality). This evidence concerns the gene CD5 and B-cell chronic lymphocytic leukemia.